CL2017002512A1 - Composiciones que contienen ibrutinib - Google Patents

Composiciones que contienen ibrutinib

Info

Publication number
CL2017002512A1
CL2017002512A1 CL2017002512A CL2017002512A CL2017002512A1 CL 2017002512 A1 CL2017002512 A1 CL 2017002512A1 CL 2017002512 A CL2017002512 A CL 2017002512A CL 2017002512 A CL2017002512 A CL 2017002512A CL 2017002512 A1 CL2017002512 A1 CL 2017002512A1
Authority
CL
Chile
Prior art keywords
sodium
lymphoma
compositions
ibrutinib
cell
Prior art date
Application number
CL2017002512A
Other languages
English (en)
Inventor
Dilip Gole
Manish Kumar Gupta
Kaustubh Tambwekar
Binuraj Krishnan Nair
Maristella Bernini
Sabine Inghelbrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2017002512A1 publication Critical patent/CL2017002512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>En la presente descripción se describen composiciones farmacéuticas que contienen Ibrutinib y procesos para prepararlas. Las composiciones pueden usarse en el tratamiento de una variedad de afecciones que incluyen, sin limitación, trastornos proliferativos de células B, tales como linfoma no Hodgkin (linfoma difuso de células B grandes, linfoma folicular, linfoma de células del manto o linfoma de Burkitt), macroglobulinemia de Waldenstrom, mieloma de células plasmáticas, leucemia linfocítica crónica, linfoma o leucemia. Estas composiciones se diseñan para la ingestión por vía oral. Las composiciones se contienen dentro de una cápsula, tal como una cápsula estándar o dispersable, o en una formulación líquida, tal como una suspensión. En una modalidad, la composición farmacéutica contiene Ibrutinib, una sal, profármaco, o metabolito de este, celulosa microcristalina, croscarmelosa sódica, laurilsulfato sódico y estearato magnésico. En otra modalidad, la composición farmacéutica contiene Ibrutinib, una sal, profármaco o metabolito de este, celulosa microcristalina, carboximetilcelulosa sódica, hidroxipropilmetilcelulosa, monohidrato de ácido cítrico, fosfato de hidrógeno disódico, sucralosa, parahidroxibenzoato de metilo sódico, parahidroxibenzoato de etilo sódico, ácido clorhídrico concentrado, hidróxido de sodio y agua.</p>
CL2017002512A 2015-04-06 2017-10-05 Composiciones que contienen ibrutinib CL2017002512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
CL2017002512A1 true CL2017002512A1 (es) 2018-03-16

Family

ID=55806788

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002512A CL2017002512A1 (es) 2015-04-06 2017-10-05 Composiciones que contienen ibrutinib

Country Status (29)

Country Link
US (6) US20160287594A1 (es)
EP (3) EP4272835A3 (es)
JP (3) JP2018513852A (es)
KR (2) KR20240013859A (es)
CN (2) CN107530293A (es)
AU (4) AU2016246669B2 (es)
CA (1) CA2981601A1 (es)
CL (1) CL2017002512A1 (es)
DK (1) DK3892302T3 (es)
EA (1) EA033992B1 (es)
ES (1) ES2964472T3 (es)
FI (1) FI3892302T3 (es)
HK (1) HK1250925A1 (es)
HR (1) HRP20231207T1 (es)
HU (1) HUE063751T2 (es)
IL (2) IL295941A (es)
LT (1) LT3892302T (es)
MA (2) MA54411B1 (es)
MD (1) MD3892302T2 (es)
MX (2) MX2017012822A (es)
PH (1) PH12017501811A1 (es)
PL (1) PL3892302T3 (es)
PT (1) PT3892302T (es)
RS (1) RS64653B1 (es)
SG (2) SG10202103458QA (es)
SI (1) SI3892302T1 (es)
SM (1) SMT202300422T1 (es)
UA (1) UA125681C2 (es)
WO (1) WO2016164404A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HK1250925A1 (zh) 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
EP3523280B1 (en) 2016-10-06 2026-03-11 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
CA3089537A1 (en) * 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
BR112020024481A2 (pt) * 2018-06-15 2021-03-02 Janssen Pharmaceutica Nv formulações/composições compreendendo ibrutinib
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
EP3886992A1 (en) * 2018-11-30 2021-10-06 Janssen Biotech, Inc. Methods of treating follicular lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
EP1877059B8 (en) 2005-04-28 2010-05-19 Wyeth a Corporation of the State of Delaware Micronized tanaproget and compostions containing same
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX391121B (es) * 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
EP4223339B1 (en) 2013-03-14 2025-01-29 Fisher & Paykel Healthcare Limited Catheter mount with suction port
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
WO2015022942A1 (ja) * 2013-08-12 2015-02-19 横浜ゴム株式会社 プライマー組成物
US9415050B2 (en) * 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
US20160032404A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HK1250925A1 (zh) 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS

Also Published As

Publication number Publication date
SI3892302T1 (sl) 2023-11-30
UA125681C2 (uk) 2022-05-18
MX2021015250A (es) 2022-01-24
IL254695B (en) 2022-10-01
PL3892302T3 (pl) 2024-03-11
IL295941A (en) 2022-10-01
PT3892302T (pt) 2023-11-15
HRP20231207T1 (hr) 2024-01-19
HUE063751T2 (hu) 2024-01-28
EA201792224A1 (ru) 2018-06-29
RS64653B1 (sr) 2023-10-31
CN107530293A (zh) 2018-01-02
US20220211713A1 (en) 2022-07-07
EP3892302B8 (en) 2023-10-18
MA54411A (fr) 2021-10-13
KR20240013859A (ko) 2024-01-30
KR102632745B1 (ko) 2024-02-01
AU2016246669A1 (en) 2017-10-12
FI3892302T3 (fi) 2023-11-03
CA2981601A1 (en) 2016-10-13
AU2024200883A1 (en) 2024-02-29
MA41901A (fr) 2021-04-14
MA54411B1 (fr) 2023-11-30
US20260048055A1 (en) 2026-02-19
KR20170134582A (ko) 2017-12-06
AU2021250925B2 (en) 2023-11-16
JP2018513852A (ja) 2018-05-31
SMT202300422T1 (it) 2024-01-10
WO2016164404A1 (en) 2016-10-13
AU2021250925A1 (en) 2021-11-11
AU2016246669B2 (en) 2021-07-15
SG11201707989PA (en) 2017-10-30
EP4272835A2 (en) 2023-11-08
MX2017012822A (es) 2018-06-13
HK1250925A1 (zh) 2019-01-18
EP3892302B1 (en) 2023-09-06
EP3280446A1 (en) 2018-02-14
SG10202103458QA (en) 2021-05-28
US20230263804A1 (en) 2023-08-24
US20160287594A1 (en) 2016-10-06
BR112017021325A2 (pt) 2018-06-26
IL254695A0 (en) 2017-11-30
US12364698B2 (en) 2025-07-22
EP4272835A3 (en) 2023-12-20
EA033992B1 (ru) 2019-12-17
PH12017501811A1 (en) 2018-04-23
EP3892302A1 (en) 2021-10-13
JP2024026087A (ja) 2024-02-28
IL254695B2 (en) 2023-02-01
LT3892302T (lt) 2023-11-10
CN113546054A (zh) 2021-10-26
US20200171036A1 (en) 2020-06-04
JP7438178B2 (ja) 2024-02-26
MD3892302T2 (ro) 2024-03-31
JP2022031690A (ja) 2022-02-22
AU2026200996A1 (en) 2026-03-05
DK3892302T3 (da) 2023-11-13
US20170252344A1 (en) 2017-09-07
ES2964472T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
CL2017002512A1 (es) Composiciones que contienen ibrutinib
UY36275A (es) Compuestos aminopirimidinilo
MX385678B (es) Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
UA118380C2 (uk) Заміщені сполуки дигідроізохінолінону
EP3283065A4 (en) Methods for formulating orally ingestible compositions comprising lipophilic active agents
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
CL2013002337A1 (es) Una composicion de intercambio de cationes que comprende silicato de zirconio; producto farmaceutico; metodo de tratamiento de hipercalemia; metodo de elaboracion de la composicion, composicion de silicato de zirconio microporoso; reactor; y metodo de preparacion de la composicion dentro del reactor.
NZ721952A (en) Delayed release compositions of linaclotide
NZ737322A (en) Notch pathway signaling inhibitor compounds
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
WO2017147098A8 (en) Deoxydehydration of sugar derivatives
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
ZA201804632B (en) Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
UY35183A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
MX380172B (es) Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.
GR1008186B (el) Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
IN2013MU03610A (es)
AR134057A2 (es) Composición farmacéutica en solución acuosa